FHIP2A
FHF complex subunit HOOK interacting protein 2A
Also known as: bA106M7.3, FAM160B1, FHI2A_HUMAN, KIAA1600
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q5W0V3
- Gene
- FHIP2A
- Ensembl
- ENSG00000151553
- Chromosome
- 10
- Canonical length
- 765 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Nuclear speckles,Cytosol
OverviewNCBI Gene
No narrative summary is available for FHIP2A in this catalog release; identity and structured annotations are shown without generated factual claims.
Canonical amino-acid sequenceUniProt
765 residues, UniProt reviewed canonical sequence.
>Q5W0V3|FHIP2A
1 MFSKFTSILQ HAVEALAPSL PLQEDFVYHW KAITHYYIET SDDKAPVTDT NIPSHLEQML
61 DILVQEENER ESGETGPCME YLLHHKILET LYTLGKADCP PGMKQQVLVF YTKLLGRIRQ
121 PLLPHINVHR PVQKLIRLCG EVLATPTENE EIQFLCIVCA KLKQDPYLVN FFLENKMKSL
181 ASKGVPNVIS EDTLKGQDSL STDTGQSRQP EELSGATGME QTELEDEPPH QMDHLSTSLD
241 NLSVTSLPEA SVVCPNQDYN LVNSLLNLTR SPDGRIAVKA CEGLMLLVSL PEPAAAKCLT
301 QSTCLCELLT DRLASLYKAL PQSVDPLDIE TVEAINWGLD SYSHKEDASA FPGKRALISF
361 LSWFDYCDQL IKEAQKTAAV ALAKAVHERF FIGVMEPQLM QTSEMGILTS TALLHRIVRQ
421 VTSDVLLQEM VFFILGEQRE PETLAEISRH PLRHRLIEHC DHISDEISIM TLRMFEHLLQ
481 KPNEHILYNL VLRNLEERNY TEYKPLCPED KDVVENGLIA GAVDLEEDPL FTDISPENTL
541 PNQEWLSSSP PATPDHPKND GKTEVHKIVN SFLCLVPDDA KSSYHVEGTG YDTYLRDAHR
601 QFRDYCAICL RWEWPGSPKA LEKCNLEAAF FEGHFLKVLF DRMGRILDQP YDVNLQVTSV
661 LSRLSLFPHP HIHEYLLDPY VNLAPGCRSL FSVIVRVVGD LMLRIQRIQD FTPKLLLVRK
721 RLLGLEPEGP IIDHITLLEG VIVLEEFCKE LAAIAFVKYH ASSTPLocalizationUniProt · AlphaFold · HPA
Whether an antibody against FHIP2A can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Unknown
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.33
- Highest tissue expression
- 50 nTPM
Expression across tissuesHPA
Tissue
- bone marrow: 50 nTPM
- skeletal muscle: 20 nTPM
- liver: 18 nTPM
- testis: 18 nTPM
- smooth muscle: 16 nTPM
- endometrium: 15 nTPM
Single-cell type
- neutrophils: 161 nCPM
- neutrophil progenitors: 142 nCPM
- adrenal cortex cells: 81 nCPM
- myonuclei: 79 nCPM
- adipocytes: 72 nCPM
- alveolar cells type 1: 69 nCPM
Immune cell
- basophil: 20 nTPM
- neutrophil: 15 nTPM
- T-reg: 11 nTPM
- memory CD8 T-cell: 9.2 nTPM
- memory CD4 T-cell: 7.4 nTPM
- naive CD8 T-cell: 5.5 nTPM
Brain region
- amygdala: 33 nTPM
- basal ganglia: 32 nTPM
- cerebral cortex: 31 nTPM
- hippocampal formation: 29 nTPM
- thalamus: 29 nTPM
- midbrain: 29 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about FHIP2A.
Disease | GeneticClinVar
1 pathogenic / likely-pathogenic of 88 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.25
- gnomAD pLI
- 1
- DepMap mean gene effect
- 0.05
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
Protein domainsUniProt · Pfam · InterPro
InteractionsUniProt · HPA
Protein binding partners of FHIP2A in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads FHIP2A as an antibody target. Whether an autoantibody or antibody against FHIP2A could matter depends on whether native FHIP2A is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
FHIP2A is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label FHIP2A as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...